Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Ascletis, Ascentage, Duality, Immuneoncia, Innovent, Kura, Nasus, Otsuka, Remegen, Teva.
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Agenus, Alvotech, Bioage, Bionet, Cullinan, Dr. Reddy’s, Fortress Biotech, Genrix, Harmony, Intragrand Pharma (Suzhou), Jikang, Lupin, Kiora, Obi, PT Bio Farma, Senju, Sun Pharmaceutical, Talentec Sdn., Titan, Transpire Bio, Zydus.
BioWorld covers the Trump administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe.
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
Biopharma’s nonprofit deal and grant activity continues to settle into a post-pandemic rhythm, with both showing a sustained decline from the elevated levels seen during and even after the COVID-19 era.
Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated non-small-cell lung cancer. The partnership in the expanding ADC space began nearly two years ago in a $22 billion deal.
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences Ltd. conducted a further analysis that shows a positive trend toward efficacy.
RSS
